Kidron

What Kidron does

Kidron Capital Assets LP is a specialist early-stage healthcare venture capital firm headquartered in Tel Aviv, Israel, founded in 2021 by Dr. Anula Jayasuriya and Maria Gajda Horowitz as Founding Managing Partners. The firm invests in companies where sex-specific biology, unmet clinical need, and inefficient capital allocation create overlooked opportunities across five verticals: medical devices, diagnostics, digital health, care delivery, and therapeutics, all targeted at women's health conditions.

The firm operates as a conventional emerging-manager venture fund structure rather than a technology platform. Its differentiated offering is investment thesis depth and clinical rigor in women's health, paired with cross-border deal access. The firm deploys capital directly into portfolio companies through equity investments from its venture funds and is currently raising Fund II, its second dedicated women's health fund, following Fund I.

Revenue mechanics follow the standard VC model: management fees on committed/invested capital plus carried interest on successful exits. The firm markets itself via direct investor outreach ([email protected]) and a specialist positioning emphasizing "specialist focus, clinical rigor, cross-border access." No proprietary technology, AI tools, or non-fund revenue streams are described; the entire operating model is fund management and equity returns.

Name

Kidron

Legal name

Kidron Capital

Website

https://kidron-capital.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Kidron Capital is an Israel-based, early-stage venture capital firm investing in women's health and sex-specific biology across devices, diagnostics, digital health, care delivery, and therapeutics, currently raising its second fund.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital
• Women's health
• Early-stage healthcare
• Biotech investment
• Healthcare innovation

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales

Revenue model

1. Fund Management / VC Returns: As a venture capital firm raising Fund II, Kidron Capital generates returns through equity investments in early-stage women's health companies. Revenue is derived from fund management fees and carried interest on successful portfolio exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Kidron Capital is a specialist early-stage healthcare venture capital firm that deploys capital into companies focused on women's health and sex-specific biology. The firm invests across medical devices, diagnostics, digital health, care delivery, and therapeutics, targeting opportunities where sex-specific biology, unmet clinical need, and inefficient capital allocation intersect. Currently raising Fund II.

Product overview

Kidron Capital is a specialist venture capital firm (not a technology product company). The firm operates as a unified investment offering, deploying capital from its early-stage healthcare fund into women's health companies. Rather than a platform with modular products, Kidron's 'offering' consists of its investment strategy, clinical expertise, and cross-border access capabilities. The firm is currently raising its second fund (Fund II).

Differentiator

Problem solved

Functional benefit

Products and services

• Kidron Capital Fund II Specialist early-stage healthcare venture fund deploying equity capital into women's health and sex-specific biology companies across medical devices, diagnostics, digital health, care delivery, and therapeutics. The fund is currently raising.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Female Founders Fund: Early-stage venture fund with a mandate focused on women-led and women-serving companies. Directly comparable to Kidron because both operate specialist mandates at the intersection of gender-focused investing and early-stage venture, though Female Founders Fund is sector-agnostic while Kidron narrows further to women's health.
• Rhia Ventures: Venture and impact fund focused on reproductive and women's health. Closely comparable to Kidron's sex-specific biology and unmet clinical need thesis, with similar early-stage orientation and LP base overlap.
• Define Ventures: Early-stage venture firm focused on healthcare technology and digital health. Comparable as a specialist early-stage healthcare investor with deep operating expertise, though broader than Kidron's women's health focus.
• Genoa Ventures: Early-stage venture firm focused on life sciences, including diagnostics and women's health. Comparable because of its specialist early-stage life sciences/healthcare mandate and similar size/emerging-manager profile.
• aMoon Ventures: Israeli healthtech and biotech venture fund. Highly comparable because it shares Kidron's Tel Aviv base and operates as a specialist Israeli healthcare investor, though with larger AUM and broader healthcare scope.
• Peregrine Ventures: Israeli early-stage healthcare and medtech investor. Comparable regional specialist healthcare peer with similar thesis on underfunded Israeli healthtech innovation.

Emerging players

• Rock Health: Venture fund and advisory focused exclusively on digital health. Comparable because of the digital-health adjacency to Kidron's digital health investment bucket, though Rock Health is broader and more digital-only.

Broad incumbents

• Lux Capital: Established venture firm with deep healthcare and life sciences practice. Comparable as a competitor for healthcare deals, but operates at much larger scale and across sectors beyond women's health.
• Khosla Ventures: Large venture firm with broad healthcare and biotech practice. Comparable as a competitive bidder for women's health deals, but with substantially larger fund sizes and broader sector exposure.
• New Enterprise Associates (NEA): Large venture firm with significant healthcare practice. Comparable as a competitor for early-stage healthcare rounds, though far broader and with much deeper capital reserves than Kidron.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kidron-capital-assets-lp

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kidron